On May 30, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 31-June 4 in Chicago (Press release, Guardant Health, MAY 30, 2024, View Source [SID1234643892]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Featured presentations will share data supporting the utility of therapy response monitoring with circulating tumor DNA (ctDNA) using Guardant Infinity and the use of the GuardantINFORM clinical-genomic database to characterize drivers and resistance mechanisms and their association with real-world outcomes in a variety of solid tumor types. Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.
"The robust data we present at ASCO (Free ASCO Whitepaper) will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "Several studies will highlight the tremendous potential of epigenomic analysis using our Guardant Infinity platform to quantify tumor fraction and characterize therapy resistance mechanisms in order to improve treatment response across multiple cancer types."
Featured presentations include:
An oral presentation of a study using the Guardant360 liquid biopsy and exploring racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer (Abstract 1017, Monday, June 3, 11:30 am – 1:00 pm, Hall D1)
Interim data readout from the collaboration between Guardant Health and the Parker Institute for Cancer Immunotherapy (PICI) to identify genomic and epigenomic biomarkers using Guardant Infinity for quantification of tumor fraction and association with outcomes from the RADIOHEAD real-world advanced pan-cancer cohort (Abstract 2570, Saturday, June 1, 9:00 am – 12:00 pm, Hall A)
Complete list of Guardant Health and collaborator presentations at ASCO (Free ASCO Whitepaper)
Abstract
Title (Hall A unless otherwise noted)
Product
Saturday, June 1 | 9:00 am – 12:00 pm
2570
Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort
Guardant Infinity
3041
Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers
Guardant Infinity
Saturday, June 1 | 1:30 pm – 4:30 pm
LBA3557
A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D
Guardant360 CDx
3519
Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers
Guardant360 & Guardant360/CDx
3602
Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): implications from PRECISION study
Guardant360 & Guardant Reveal
3545
Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort
GuardantINFORM
Sunday, June 2 | 9:00 am – 12:00 pm
1037
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)
Guardant Infinity
1043
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor
Guardant Infinity
1071
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
GuardantINFORM
5069
Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC)
GuardantINFORM
Monday, June 3 | 9:00 am – 12:00 pm | Hall A
5592
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC)
Guardant Infinity
Monday, June 3 | 11:30 am – 1:00 pm | Hall D1
1017
Rapid Oral Abstract Session: Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer
Guardant360
Online only
e13097
Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy
Guardant360 & Guardant360 CDx
e12566
Molecular profiling in ABC: Is complementary testing with tissue and plasma necessary and clinically relevant?
Guardant360
e13702
Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients
GuardantINFORM
e20088
Use of cell-free tumor DNA in early detection of lung cancer
Shield (next generation)
The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the ASCO (Free ASCO Whitepaper) website.
For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO (Free ASCO Whitepaper) booth #28115.